Sulesomab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sulesomab
Accession Number
DB13976
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • IMMU-MN3
  • Immunoglobulin G1 (mouse monoclonal IMMU-MN3 Fab' fragment gamma-chain anti-human NCA-90 granulocyte cell antigen), disulfide with mouse monoclonal IMMU-MN3 light chain
Product Ingredients
IngredientUNIICASInChI Key
Technetium Tc-99m sulesomab0G1945O6IBNot AvailableNot applicable
Categories
UNII
709B6VM65P
CAS number
167747-19-5

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Sulesomab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Sulesomab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Sulesomab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Sulesomab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Sulesomab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Sulesomab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulesomab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Sulesomab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Sulesomab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Sulesomab.
Food Interactions
Not Available

References

General References
  1. Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ: Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections. Med Princ Pract. 2008;17(6):447-52. doi: 10.1159/000151565. Epub 2008 Oct 3. [PubMed:18836272]
External Links
Wikipedia
Sulesomab
ATC Codes
V09HA04 — Technetium (99mtc) sulesomab
FDA label
Download (84.7 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on January 18, 2018 10:03 / Updated on November 02, 2018 09:13